Skip to main content

Table 1 Baseline characteristics and parameters in type 2 diabetic patients with plaque progression and those with no plaque progression

From: Serum MPO levels and activities are associated with angiographic coronary atherosclerotic plaque progression in type 2 diabetic patients

 

No plaque progression (n = 87)

Plaque progression (n = 161)

P value

Male, n (%)

58 (66.7)

114 (70.8)

0.500

Age, years

65.71 ± 8.38

66.60 ± 9.77

0.476

Body mass index, kg/m2

24.63 ± 2.95

25.24 ± 3.31

0.154

Smoking, n (%)

17 (19.5)

65 (40.4)

0.001

Hypertension, n (%)

54 (62.1)

128 (79.5)

0.003

Dyslipidemia, n (%)

14 (16.1)

34 (21.1)

0.339

Severity of CHD, n (%)

  

0.217

 1-Vessel

25 (28.7)

38 (23.6)

 

 2-Vessel

32 (36.8)

49 (30.4)

 

 3-Vessel

30 (34.5)

74 (46.0)

 

Systolic blood pressure, mm Hg

138.74 ± 20.17

138.84 ± 19.85

0.967

Diastolic blood pressure, mm Hg

74.91 ± 16.37

75.42 ± 10.75

0.766

Fasting blood glucose, mmol/L

7.12 ± 1.80

7.04 ± 2.29

0.780

HbA1c, %

7.27 ± 1.17

7.43 ± 1.45

0.367

Serum creatinine, μmol/L

76.60 ± 19.79

84.14 ± 41.80

0.113

Serum BUN, mmol/L

6.96 ± 3.04

6.67 ± 3.53

0.509

Serum uric acid, μmol/L

334.90 ± 92.63

342.45 ± 91.04

0.536

eGFR, mL/min/1.73m2

84.64 ± 15.69

80.25 ± 18.56

0.062

Triglyceride, mmol/L

1.69 ± 0.88

1.60 ± 0.98

0.465

Total cholesterol, mmol/L

3.84 ± 1.17

3.96 ± 1.18

0.455

HDL cholesterol, mmol/L

1.08 ± 0.28

1.06 ± 0.27

0.581

LDL cholesterol, mmol/L

2.22 ± 0.89

2.37 ± 0.95

0.216

Apolipoprotein A, g/L

1.25 ± 0.23

1.20 ± 0.23

0.095

Apolipoprotein B, g/L

0.74 ± 0.22

0.79 ± 0.23

0.109

Lipoprotein (a), g/L

0.22 ± 0.24

0.25 ± 0.26

0.458

CRP, mg/mL

0.63 (0.28–2.43)

1.14 (0.49–4.08)

0.001

Medication, n (%)

ACE inhibitors/ARBs

55 (63.2)

112 (69.6)

0.309

β-blockers

43 (49.4)

96 (59.6)

0.122

Statins

80 (92.0)

146 (90.7)

0.985

Antiplatelet

82 (94.3)

154 (95.7)

0.758

Metformin

31 (35.6)

54 (33.5)

0.740

Insulin

19 (21.8)

36 (22.4)

0.925

MPO level, ng/mL

20.20 (19.20–27.00)

33.30 (21.45–60.00)

 < 0.001

MPO activity, mU/mL

6.94 ± 5.20

10.37 ± 7.26

 < 0.001

Follow-up

 Duration, months

12.18 ± 1.29

12.32 ± 1.24

0.428

 Changes in MLD, mm

 − 0.06 ± 0.09

0.67 ± 0.25

 < 0.001

 Changes in stenosis diameter (%)

0.88 ± 3.29

 − 22.70 ± 9.86

 < 0.001

 Changes in CCSS

 − 0.01 ± 0.08

 − 0.33 ± 0.15

 < 0.001

  1. Values are given as mean ± standard deviation (SD), median (25th–75th percentile) or number (percentage)
  2. Change of QCA measurement is defined as baseline QCA measurement minus follow-up measurement
  3. CHD Coronary atherosclerotic heart disease, ACE Angiotensin converting enzyme, ARB Angiotensin receptor blocker, BUN Blood urea nitrogen, CRP C-reactive protein, eGFR Estimated glomerular filtration rate, HbA1c Glycosylated hemoglobin, HDL High-density lipoprotein, LDL Low-density lipoprotein, CCSS Cumulative coronary stenosis score, MLD Minimal lumen diameter, QCA Quantitative coronary analyses